An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
Status:
Completed
Trial end date:
2009-05-05
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the bronchodilator efficacy of three doses
(50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and
tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives
include comparing the effects on dyspnea and health status.